ChemotherapyFDA-approvedFirst-line
Pemetrexed
How it works
Interferes with the production of DNA and RNA in cancer cells, preventing them from growing and dividing.
Cancer types
Lung Cancer— All patients
Efficacy
In clinical trials, around 40% of patients achieved an objective response, with median overall survival of approximately 13 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing a New Approach to Treat Lung Cancer Spreading to the Brain and Spinal Cord | Lung Cancer | preclinical | — | Source → |
| Pemetrexed Enhances γδ T Cell Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| Testing a New Treatment Combination for Unresectable Pleural Mesothelioma | Lung Cancer | phase-3 | — | Source → |
| Rare Skin Reaction Linked to Lung Cancer Treatment | Lung Cancer | observational | — | Source → |
| New Treatment Combination Tested for Lung Cancer Patients with Brain Metastases | Lung Cancer | phase-1 | — | Source → |
| Testing Methoxyamine with Cisplatin and Pemetrexed in Advanced Cancer Patients | Lung Cancer | phase-1 | — | Source → |
| Testing Sacituzumab Tirumotecan in Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Traditional Chinese Medicine May Help Reduce Chemotherapy Side Effects in Lung Cancer Patients | Lung Cancer | phase-3 | The incidence of neurotoxicity was 29.1% in the treatment group, significantly lower than 51.8% in the control group. | Source → |
| Taxane Chemotherapy May Be More Effective Than Pemetrexed in Lung Cancer | Lung Cancer | observational | Taxanes showed numerically longer progression-free survival (PFS; median 8.8 vs 7.9 months) and overall survival (OS; 18.8 vs 15.9 months) versus pemetrexed. | Source → |
| Pemetrexed Side Effects Study Identifies New Safety Signals | Lung Cancer | observational | — | Source → |
| Combining Medications Improves Lung Cancer Treatment for Some Patients | Lung Cancer | phase-3 | Combination therapy significantly prolonged median progression-free survival compared with monotherapy (19.78 vs 16.53 months; hazard ratio, 0.58; 95% confidence interval, 0.34-0.97). | Source → |
| New Treatment for Lung Cancer | Lung Cancer | observational | — | Source → |
| New Treatment Combination Shows Promise for Lung Cancer Patient | Lung Cancer | observational | The treatment successfully prolonged the patient's survival by 3 months. | Source → |
| New Biomarkers for Lung Cancer Treatment Identified | Lung Cancer | lab-study | The Random forest model had an area under the curve (AUC) of 0.981 for diagnosing patients with NSCLC and 0.954 for evaluating pemetrexed efficiency. | Source → |
| Rare Lung Cancer Case Shows Long-Term Survival with Pemetrexed Treatment | Lung Cancer | observational | She has been taking entrectinib for over 20 months. | Source → |
| Combining Osimertinib and Pemetrexed May Help Treat Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Alternate Dosing Schedule for Lung Cancer Treatment May Improve Survival | Lung Cancer | observational | OS trended towards better survival among patients receiving the alternate schedule regimen (11.9 vs 18.1 months, p =0.3). | Source → |
| Pemetrexed May Help Treat Non-Small-Cell Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Pemetrexed's Effect on Lung Cancer Cells Varies with Glucose Levels | Lung Cancer | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.